Moberg Pharma AB (publ) (MOB) - Total Liabilities
Based on the latest financial reports, Moberg Pharma AB (publ) (MOB) has total liabilities worth Skr17.04 Million SEK (≈ $1.83 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Moberg Pharma AB (publ) - Total Liabilities Trend (2008–2025)
This chart illustrates how Moberg Pharma AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See MOB working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Moberg Pharma AB (publ) Competitors by Total Liabilities
The table below lists competitors of Moberg Pharma AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NDL Ventures Limited
NSE:NDLVENTURE
|
India | Rs58.64 Million |
|
Sinsin Pharmaceutical Co. Ltd
KQ:002800
|
Korea | ₩65.10 Billion |
|
ZENTEK LTD.
F:ZAY0
|
Germany | €5.04 Million |
|
Space Hellas SA
AT:SPACE
|
Greece | €158.35 Million |
|
Shalimar Paints Limited
NSE:SHALPAINTS
|
India | Rs4.03 Billion |
|
Rama Phosphates Limited
NSE:RAMAPHO
|
India | Rs2.41 Billion |
|
Feerum S.A.
WAR:FEE
|
Poland | zł42.23 Million |
|
Southern Rubber Industry JSC
VN:CSM
|
Vietnam | ₫2.45 Trillion |
Liability Composition Analysis (2008–2025)
This chart breaks down Moberg Pharma AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Moberg Pharma AB (publ).
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.75 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Moberg Pharma AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Moberg Pharma AB (publ) (2008–2025)
The table below shows the annual total liabilities of Moberg Pharma AB (publ) from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr17.04 Million ≈ $1.83 Million |
-11.55% |
| 2024-12-31 | Skr19.27 Million ≈ $2.07 Million |
-19.73% |
| 2023-12-31 | Skr24.01 Million ≈ $2.58 Million |
-22.15% |
| 2022-12-31 | Skr30.84 Million ≈ $3.32 Million |
+83.15% |
| 2021-12-31 | Skr16.84 Million ≈ $1.81 Million |
-80.19% |
| 2020-12-31 | Skr85.00 Million ≈ $9.15 Million |
+241.22% |
| 2019-12-31 | Skr24.91 Million ≈ $2.68 Million |
-96.21% |
| 2018-12-31 | Skr657.60 Million ≈ $70.77 Million |
-1.98% |
| 2017-12-31 | Skr670.85 Million ≈ $72.19 Million |
+0.04% |
| 2016-12-31 | Skr670.55 Million ≈ $72.16 Million |
+1402.43% |
| 2015-12-31 | Skr44.63 Million ≈ $4.80 Million |
-20.26% |
| 2014-12-31 | Skr55.97 Million ≈ $6.02 Million |
-20.17% |
| 2013-12-31 | Skr70.11 Million ≈ $7.55 Million |
-31.61% |
| 2012-12-31 | Skr102.53 Million ≈ $11.03 Million |
+554.46% |
| 2011-12-31 | Skr15.67 Million ≈ $1.69 Million |
+33.96% |
| 2010-12-31 | Skr11.69 Million ≈ $1.26 Million |
+129.85% |
| 2009-12-31 | Skr5.09 Million ≈ $547.55K |
-30.83% |
| 2008-12-31 | Skr7.36 Million ≈ $791.64K |
-- |
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.